# Kangso Medical Inspection

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/kangso-medical-inspection

- Industry: Healthcare
- Headquarters: Beijing, China
- Website: www.kangso.net
- Latest round: Series A (Aug 20, 2018)
- Investors on record: 2

## About

Kangso Medical Inspection is a medical laboratory focused on delivering precise diagnostic testing and analysis, enhancing patient care through reliable results and advanced healthcare solutions.Kangso Medical Inspection, headquartered in Beijing, China, was founded in 2013 by Wei Wei, who has been involved in the medical field prior to establishing this firm. The company has made 2 deals, with its most recent funding event occurring on August 20, 2018. It operates as an independent entity without subsidiaries.Kangso Medical Laboratory specializes in medical testing and diagnostics, providing core services that enhance patient outcomes through accurate and timely results. Their primary offerings include a variety of clinical laboratory tests and analyses that facilitate disease diagnosis, monitoring, and management for healthcare professionals. By utilizing advanced technologies in molecular biology and biochemistry, Kangso addresses healthcare challenges such as early disease detection and personalized medicine. Their client base includes hospitals and clinics across urban centers in China, targeting major metropolitan areas like Beijing and Shanghai, where there is a high demand for quality diagnostic services. Ultimately, their services assist patients in achieving diagnostic clarity and ongoing health management.Kangso Medical Laboratory generates revenue through direct service agreements with healthcare providers, such as hospitals and clinics, on a fee-for-service basis. Clients are billed for specific tests performed and results provided. The company also engages in partnerships for bulk testing services with larger institutions, resulting in negotiated pricing. Each service is priced according to its complexity and resource requirements, aligning with industry standards for laboratory diagnostics. Key offerings include specialized tests for oncology, infectious diseases, and genetic testing.Kangso Medical Inspection plans to utilize the funds raised in August 2018 from new investor Shenzhen Hua Xia Ren He Capital to expand its product offerings and enhance its technological capabilities. The company is working on launching innovative diagnostic tests aimed at improving early detection of diseases and personalized medicine solutions. Additionally, Kangso is targeting expansion into other major cities across China, aiming for significant market penetration by 2025, in response to increasing healthcare demands.

## Funding rounds

- Series A, Aug 20, 2018 — Renhe Capital
- Series A, Jan 25, 2016 — Everest VC

## Investors

- Everest VC (https://capitalatlas.ai/funds/everest-vc) — Series A
- Renhe Capital (https://capitalatlas.ai/funds/renhe-capital) — Series A